Completed PHASE1 INTERVENTIONAL 2-arm NCT04023669

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

St. Jude ELIOT: Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Sponsor: Eli Lilly and Company

Conditions Brain Cancer Brain Tumor Brain Tumor, Pediatric Brain Tumor, Recurrent Brain Tumor, Refractory CNS Cancer CNS Neoplasm CNS Tumor Medulloblastoma Medulloblastoma Recurrent Medulloblastoma, Non-WNT/Non-SHH Medulloblastoma, Non-WNT/Non-SHH, Group 3 Medulloblastoma, Non-WNT/Non-SHH, Group 4

Interventions Cyclophosphamide Gemcitabine Prexasertib filgrastim peg-filgrastim

Updated 19 times since 2019 Last updated: Feb 6, 2025 Started: Aug 8, 2019 Primary completion: May 1, 2023 Completion: Jan 13, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Brain Cancer and Brain Tumor and is currently completed. Eli Lilly and Company leads this study, which shows 19 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

19 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Oct 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

▶ Show 14 earlier versions

Dec 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE1
Jun 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE1
Mar 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE1
Nov 2022 — Mar 2023 [monthly]

Active Not Recruiting PHASE1
Jun 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE1
May 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE1
Apr 2022 — May 2022 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jun 2021 — Apr 2022 [monthly]

Recruiting PHASE1
Jan 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Apr 2020 — Oct 2020 [monthly]

Recruiting PHASE1
Nov 2019 — Apr 2020 [monthly]

Recruiting PHASE1
Sep 2019 — Nov 2019 [monthly]

Recruiting PHASE1
Aug 2019 — Sep 2019 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
St. Jude Children's Research Hospital

Data source: St. Jude Children's Research Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Memphis, United States